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ABSTRACT 
Objective: To determine the predictors of concomitant use of benzodiazepines with 
chronic opioid use in Rhode Island using pharmacy level data. 
Design: Cross – sectional analysis 
Setting: Rhode Island Prescription Drug Monitoring Program (PDMP) Database, 2015 
Participants: Any person who filled a prescription for an opioid (>30 days’ supply), a 
benzodiazepine or both at a licensed retail pharmacy in Rhode Island during 2015.   
Main outcome measure: Concomitant use of opioid analgesics and benzodiazepines, 
defined as the receipt of any benzodiazepine and opioid pharmacy dispensing having a 
days’ supply which overlaps by at least 1 day.  
Results: Of 139,410 patients who were included in our analysis, 15.5% had overlapping 
(concomitant) opioid and benzodiazepine prescriptions during 2015.  Patients who were 
younger than 45 years of age, and who see more than three prescribers were less likely 
to be prescribed both opioids and benzodiazepines, in which the days supply overlap.  
Additionally, each additional prescription a person receives for a controlled substance 
increased the odds that they were prescribed concomitant therapy. 
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CHAPTER 1 
 
INTRODUCTION 
 
In August, 2016, the Food and Drug Administration (FDA) published a drug 
safety communication warning of the serious risks associated with the concomitant use 
of opioids and benzodiazepines after published literature identified an increase in the 
combined use of these central nervous system depressant drugs. 1 Combined use of 
these two classes of drugs may lead to respiratory depression, coma and even death, 
which are all side effects that may be avoided if proper prescribing and usage 
guidelines are respected. 1 
Since 2014, Rhode Island has maintained a fully operational Prescription Drug 
Monitoring Database (PDMP), which captures medication dispensing of controlled 
substances, as reported by pharmacists. This study measured the extent of concomitant 
use of opioid and benzodiazepine medications and determined if patients prescribed 
both of these types of medications differ from patients using opioids solely, 
benzodiazepines solely, and opioids and benzodiazepines with no overlapping days of 
use, with regard to demographics, insurance type, and use of other controlled 
substances.  
Hypothesis:   
1. Patient demographics, number of prescribers, number of pharmacies 
utilized, total number of prescriptions filled, and stimulant use does not 
differ between those who concomitantly use opioids and benzodiazepines 
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and those who solely use opioids or benzodiazepines, or those who have 
dual, non-overlapping use of benzodiazepines and opioids. 
2. Among those who concomitantly use opioids and benzodiazepines, the 
following factors are not predictors of increased risk: opioid type, average 
number of prescriptions by duration of action, average number of 
controlled substance prescriptions by class, average days of supply by class 
and number of prescribers.
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CHAPTER 2 
 
REVIEW OF LITERATURE 
 
It has been widely publicized that the United States is experiencing an opioid 
addiction and overdose epidemic.  In a NCHS data brief from 2014, it was noted that 
opioid analgesic poisoning (intentional and unintentional) accounted for 41% of drug 
poisoning deaths in 2011.  This number represents 16,917 deaths, a 300% increase 
from 1999.2  As of 2009, drug poisoning deaths surpassed traffic accidents as the 
leading cause of injury related deaths for the first time since 1980.3   
Opioids are used to treat a wide range of pain experiences, from severe pain 
associated with cancer to moderate to severe pain associated with neuropathy, 
fibromyalgia, headaches, and musculoskeletal disorders.  Opioids are, therefore, 
prescribed to a wide range of individuals.  From 2000 to 2010, there was 104% 
increase in the number of opioid analgesic prescriptions written: 89.2 million 
prescriptions.  The number of patients receiving opioid prescriptions increased 80% in 
this same time period, to 27.5 million individuals.4 While there has been an increase in 
both the number of patients receiving prescriptions for opioids and the total number of 
prescriptions written, there is evidence to suggest being prescribed opioids did little to 
improve the health and disability status of the patient, as health status remained 
unchanged or actually decreased.4 
 Safely and effectively managing acute and chronic pain in a patient with 
comorbid conditions presents challenges.  While it may inappropriate to use opioids in 
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conjunction with a variety of medication classes, combined use with benzodiazepines 
is particularly perilous. Jones, et al, analyzed 2010 overdose data for the United States, 
and found that among overdose deaths involving an opioid analgesic, benzodiazepines 
were also involved in 30% of cases.5 In another study, conducted by Yarbourgh, et al, 
the researchers analyzed interviews with survivors of opioid overdoses and found that 
most events involved the use of multiple drugs (83%), and often benzodiazepines 
(32%).6 Reisfield, et al, noted that opioids and benzodiazepines are the most 
commonly co-abused drugs; estimates ranging from 20-50% of patients who are 
prescribed long term opioid therapy, also received prescriptions for a benzodiazepine.7   
The concomitant use of opioids with benzodiazepines is discouraged in 
prescribing guidelines,8 but co-prescribing these drugs by both a single prescriber or 
simultaneously by multiple prescribers is not uncommon, nor is prescribing for a 
longer duration than is recommended.9   This may be due to the fact that 
benzodiazepines are characterized as relatively safe while having a high therapeutic 
index,10 and less likely than opioids to be the sole drug involved in an accidental 
overdose.11  Benzodiazepines are recommended as a second-line treatment for some 
common conditions such as insomnia, and anxiety, and when they are prescribed it is 
recommended that they are used for a short time period and not in conjunction with 
certain other classes of medicines, including opioids. Benzodiazepines alter the 
pharmacodynamic effects of opioids.  Studies have shown that the concomitant use 
amplifies the central nervous system effects of opioids.12  Additionally, opioids and 
benzodiazepines have different mechanisms of action which is problematic because 
both opioids and benzodiazepines are central nervous system depressants; these drugs 
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have the effect of depressing the central nervous system through two different 
mechanisms when the two classes of drugs are administered together.11  This can lead 
to overdose; chronic use of both opioids and benzodiazepines has been associated with 
“additive effects in sleep disordered breathing.”13  Finally, when benzodiazepines are 
prescribed for a longer period than is recommended, the patient may experience an 
increased tolerance to the dose of the drug10 and dependency.14 Risk for dependency 
may also be linked to the type of first benzodiazepine used and dose escalation 
schedule.14   
 Reports such as these have led the FDA to announce extensive changes to the 
requirements for the package labeling and medication guide of nearly four hundred 
products which contain opioid analgesics, including cough products or 
benzodiazepines.  The new materials will contain the FDA’s most serious warning – 
the boxed warning, to indicate the serious risks associated with the use of these 
medications.  In addition to the packaging changes,  this announcement was 
accompanied by the publication of a drug safety communication with the intention of  
warning prescribers and those taking these medications about the dangers of 
concomitant use of these classes of medications.1 
 The Rhode Island Prescription Drug Monitoring Program affords physicians 
and pharmacists alike the ability to actively manage their patients, and make 
prescribing decisions based on a comprehensive look at the patient’s prescription 
history.   The focus of this study was to quantify the number of patients in Rhode 
Island who were prescribed concomitant therapy with opioids and benzodiazepines in 
2015 and determine if there were patient level or prescription level predicators that 
 6 
 
indicated a patient was more likely to be prescribed concomitant therapy. 
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CHAPTER 3 
 
METHODOLOGY 
 
Study design  
A cross sectional observational study was conducted using de-identified pharmacy-
level data obtained from the Rhode Island Prescription Drug Monitoring Program 
(PDMP). For all patients who received benzodiazepine or opioid medications in 2015, 
the percentage who received a dispensing for both categories of drugs was determined, 
and characteristics associated with use of both opioid and benzodiazepine medications 
were identified. 
Data Source   
The Rhode Island PDMP database includes pharmacy-level data for all prescriptions 
filled for schedule II to IV medications at Rhode Island based pharmacies who hold a 
controlled substance registration number.  As mandated by state law, all pharmacies 
that dispense schedule II-IV medications to individuals who are “not an inpatient of a 
hospital, correctional institution or nursing facility” are required to electronically 
report 19 data elements to the PDMP within 72 hours of filling the prescription.  The 
data set does not include medications dispensed to patients of outpatient methadone 
maintenance programs. A de-identified subset of PDMP data was used, which 
included the following variables: age, gender, payer, date of prescription fill, the 
number of days covered by the prescription, medication name, and a de-identified 
prescriber drug enforcement administration identification number. 
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Study population:  
The study population was comprised of patients of any age who filled a prescription 
for an opioid medication, a benzodiazepine, or both in Rhode Island, during 2015.   
Patient identification:  
Inclusion/exclusion criteria  
The following patients were included: A.) Patients, of any age, who filled at least one 
prescription for oxycodone, hydrocodone, morphine, oxymorphone, hydromorphone, 
tapentadol, methadone, pentazocine, butorphanol, meperidine, levorphanol or codeine 
tablets, or fentanyl patches, totaling at least a 30 days’ supply during 2015.  Patients 
who filled prescriptions for buprenorphine or dose forms of opioids which suggest 
cancer treatment (such as fentanyl lozenges) were excluded; and B. Patients who filled 
at least one prescription for any benzodiazepine drug. 
Study variables:  
Outcome variables:  
The primary outcome measure was the concomitant use of opioid medications and 
benzodiazepines.  This variable was defined as the receipt of any benzodiazepine and 
opioid pharmacy dispensing having a days’ supply which overlapped by at least 1 day.  
Independent variables:   
Demographic variables included age (and age group), gender, payment type (including 
cash and insurance), number of unique opioid and/or benzodiazepine prescribers, if the 
patient received any prescriptions from the top five, ten and twenty five percent of 
opioid prescribers in Rhode Island (percentage was determined by the total number of 
opioid prescriptions written in 2015 by the prescriber in relation to the total number of 
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opioid prescriptions in 2015), type of opioid medication(s) prescribed  (short acting 
versus long acting, and also chemical type (oxycodone, hydrocodone, morphine, 
oxymorphone, hydromorphone, tapentadol, methadone, pentazocine, butorphanol, 
meperidine, levorphanol, codeine and fentanyl), total days’ supply, total number of 
dispensings for controlled substances of any type (CII-CIV), whether the drugs of 
interest were prescribed by the same or different prescribers, if the patient was a high 
utilizer of multiple pharmacies or prescribers, and the concurrent use of stimulants. 
Statistical analysis:  
A descriptive analysis was conducted to identify the overall frequency and percentage 
of each variable included in the study. Each independent variable was compared with 
concomitant use, sole use of opioids, sole use of benzodiazepines and non-
concomitant use of both opioids and benzodiazepines.  We conducted a student t-test 
for continuous variables, and a Chi-square test for categorical variables to determine 
the statistical significance of differences between the four outcome groups.  
After the initial descriptive analysis, the outcome groups were collapsed into 
one dichotomous variable: concomitant use (sole use of opioids, sole use of 
benzodiazepines and non-concomitant use of both opioids and benzodiazepines groups 
were combined to represent non-concomitant use.) 
Univariate logistic regression analysis was conducted to evaluate the 
association between each independent variable with the dependent variable and 
identify the significant risk factors of concomitant use of opioid and benzodiazepine 
medication. A predictive multivariate logistic regression model was then built using a 
backward stepwise approach with all significant independent variables identified from 
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the univariate logistic regression. Independent variables associated with combined use 
of opioid and benzodiazepine drugs at P<0.2 (for any strata) were retained in the 
model.  Diagnostic tests for collinearity were performed between independent 
variables, 2-way interactions were assessed, and diagnostics of model fit were 
examined, as guided by Akaike information criterion and the Hosmer Lemeshow test. 
The measure of association between outcome and each independent variable was 
determined by computing the odds ratio with a 95% confidence interval. Bonferroni 
Correction was applied for multiple or pairwise comparisons for independent variables 
with multiple levels.   
 A sensitivity analyses was conducted.  Specifically, the definition of 
concomitant use of opioid and benzodiazepine medications was expanded to include 0, 
≥2, or ≥3 concomitant days of opioid and benzodiazepine prescriptions.  For zero 
concomitant days, the gap between prescriptions was not greater than one day.   
Finally, a subgroup analyses was conducted to examine whether the significant 
risk factors for concomitant use of opioids and benzodiazepines differed by gender.  
 Statistical analyses were conducted in SAS 9.4 (SAS software Inc., Cary, NC). 
The statistical significance level was set at P<0.05. This protocol was submitted to the 
University of Rhode Island Institutional Review Board for review, and classified as 
not human subjects research.
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CHAPTER 4 
 
FINDINGS 
 
Hypothesis 1: 
The PDMP database that we analyzed was comprised of 2,516,314 claims for 
409,740 unique individuals, from 2015 and 2016. To identify our population of 
interest, we first reduced the database to claims from 2015 only, identifying 1,289,651 
claims for 364,128 unique individuals.  We then limited the database to include 
prescriptions for opioids and benzodiazepines of any duration. The data were then 
arranged at the patient level only, in order to tally days’ supply of each drug class and 
identify additional patients for exclusion; this yielded 326,785 unique individuals who 
had opioid use of any duration and/or benzodiazepine use.  We then removed any 
patient who had missing prescription information data, including drug NDC, date of 
fill, or days’ supply.  We also identified individuals who we presumed to be receiving 
opioids to manage cancer pain, based on the type of fentanyl prescriptions (e.g. 
lozenge).  This further reduced our database to 297,594 unique individuals.  Finally, 
we excluded individuals who did not meet the threshold of 30 days of opioid use in 
2015.  Our resulting database included 139,410 unique individuals. Of those included, 
34,825 (25%) patients filled opioid prescriptions totaling at least 30 days and no 
benzodiazepine prescriptions, 81,062 (58.1%) patients filled a benzodiazepine 
prescription and no opioid prescriptions, 1,871 (1.3%) patients filled opioid 
prescriptions totaling at least 30 days and a benzodiazepine prescription which did not 
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overlap with the opioid prescription.  These three groups of patients were combined to 
represent the non-concomitant use level of the dichotomized concomitant use outcome 
variable.  Additionally, 21,652 (15.5%) patients filled opioid prescriptions totaling at 
least 30 days, and a benzodiazepine prescription which overlapped the opioid 
prescription by at least one day.  This group was labeled the concomitant use group.  
See Figure 1. 
 Table 1 provides the frequency and percentage of the independent variables by 
each of the four groups outlined above.  The majority of our study population was 
female (63%) and the average age was 55 years (SD 18.7).  Most had commercial 
insurance (65%), filled prescriptions at fewer than 4 pharmacies (94.2%) and had 
fewer than 4 prescribers (89.4%).  The average number of prescriptions for controlled 
substances per patient during 2015 was 6.7 (SD 7.3).  Each independent variable was 
compared with each outcome of interest; all variables were statistically significantly 
associated with differences among the four outcomes groups, with the exception of 
gender.  Subsequent multivariable analysis was performed using the dichotomized 
concomitant use outcome variable.   
For the multivariate analysis, the continuous variable age was not included, 
since both age variables were significant in the univariate analysis.  Gender was not 
included since it was insignificant in the univariate analysis.  Overall, the covariates 
included in the multivariate model remained statistically significant.   
A diagnostic test for collinearity did not reveal any collinear covariates.  We 
also assessed for 2-way interactions between age and all covariates, and total number 
of prescriptions and all covariates.  Significant interaction was seen between age and 
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total number of controlled substance prescriptions, number of prescribers and 
stimulant use, and also between total number of prescriptions and pharmacy 
utilization, payment type and stimulant use.  These interactions were then entered in 
the model.  After running subsequent models, pharmacy utilization was removed as it 
was no longer significant.  The model fit was not improved by the inclusion of the 
interaction terms, according to the Hosmer and Lemeshow test (p <.0001), therefore 
the model findings without the interaction terms is presented in Table 2. 
 Results from the multivariable model revealed that patients who were 45-64 
years of age (OR 1.326, 95% CI 1.259-1.398) or greater than 64 years of age (OR 
1.85, 95% CI 1.75-1.96) were more likely to be prescribed  concomitant opioid and 
benzodiazepine prescriptions than younger patients.  Those who received controlled 
substance prescriptions from less than or equal to three prescribers (OR 0.257, 95% CI 
0.246-0.268) were less likely to be prescribed concomitant opioid and benzodiazepine 
prescriptions than those who received controlled substance prescriptions from greater 
than 3 prescribers.  However, patients who paid for the most recent prescription using 
health insurance (commercial health insurance OR 1.003, 95% CI 0.943-1.067; public 
health insurance OR 1.108, 95% CI 1.035-1.185; other health insurance OR 3.684, 
95% CI 3.249-4.177), and did not have a least one prescription filled for a stimulant 
(OR 3.285, 95% CI 3.021-3.572), had increased odds of being prescribed 
benzodiazepines and opioids concomitantly. Additionally, each additional prescription 
for a controlled substance that a person was prescribed increased the odds that they 
were prescribed concomitant therapy by 12 percent (OR 1.12, 95% CI 1.118-1.122. 
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Hypothesis 2: 
Of those individuals who were prescribed at least one instance of concomitant 
prescriptions, the average number of opioid, benzodiazepine and controlled substance 
prescriptions and the most commonly prescribed opioid and benzodiazepine 
medications were identified. The most commonly prescribed opioids were oxycodone 
and hydrocodone, with roughly 50% of the concomitant use group being prescribed at 
least one of these medications (54% and 49%, respectively).  On average, individuals 
who received concomitant opioid and benzodiazepine prescriptions, received 10 
prescriptions for opioids (SD 7) and 7 prescriptions for benzodiazepines (SD 5).  See 
Table 3.   
 We analyzed prescribers by de-identified DEA number, and determined the top 
25%, 10% and 5% of opioid prescribers, by prescription volume. In the concomitant 
use group, 21,595 (99.7% of the concomitant use group) individuals filled at least one 
opioid prescription by a provider who was in the top 25%, 7,359 (34%) filled at least 
one opioid prescription by a provider who was in the top 10% and 4,073 (18.8%) filled 
at least one opioid prescription by a provider who was in the top 5%.  See Table 4. 
We conducted a sub group analysis of those receiving concomitant opioids and 
benzodiazepines, stratifying by gender. Women, who represented 66% the 
concomitant use group, were generally older (36.6% of women were older than 64 
years of age versus 29.1% of men, p <0.0001), more likely to pay for prescriptions 
using public insurance (28.9% vs 24.3%, p <0.0001), have >3 prescribers (38.7% vs 
36.3%, p 0.0007) and fill a greater number of prescriptions for at least one stimulant 
(7.5% vs 5.8%, p <.0001).  See Table 5. 
 15 
 
  Table 6 highlights the significant differences in the type of opioids used 
among men and women, and differences in prescribing patterns. Of the most 
commonly prescribed opioids, previously mentioned, men filled a greater percentage 
of prescriptions than women for oxycodone (59.3% vs 51.3%, p <.0001), morphine 
(16% vs 13.8%, p <0.0001) and methadone (2.4% vs 1.7%, p 0.0004).  Men also filled 
more prescriptions for opioids overall than women (mean 10 prescriptions vs 7 
prescriptions, p <.0001).  Men were prescribed a greater number of days of opioids 
(mean 178.7 days’ vs 172.7 days’ supply, p 0.0025). However, women received a 
greater number of days of benzodiazepines (mean 174 days’ supply vs 161.3 days’ 
supply, p <.0001) and were prescribed concomitant therapy by different prescribers 
more frequently than men (60.7% vs 56.9%, p <.0001). 
A sensitivity analysis did not reveal any statistically significant differences 
among patients who filled concomitant benzodiazepine and opioid prescriptions with 
varying degrees of overlapping days.  See Appendix  1.
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CHAPTER 5 
 
CONCLUSION 
 
In this state-level analysis of 139,410 individuals we found that overall 15.5% 
(21,652) of individuals were prescribed opioid and benzodiazepine prescriptions 
concomitantly, which overlapped by at least one day, at least once during 2015.  This 
figure represents 2.1% of Rhode Islanders during that time.  Of those who were 
prescribed concomitant therapy, roughly twice as many women (66% to 34%) 
received these medication types concomitantly as compared with men.  Our results 
agree with published findings from the analysis of 2013-2014 data obtained from the 
Texas PDMP and a national data sample which mimicked the data available in a 
PDMP for 2015.  These analyses presented similar trends of potentially inappropriate 
concurrent prescribing of opioids and benzodiazepines (among other potentially 
inappropriate drug combinations.)   
In analyzing data from the Texas PDMP, researchers found that 15.99% of 
controlled substance users were prescribed at least one instance of potentially 
inappropriate concurrent combinations of drugs.  Their analysis included a greater 
number of inappropriate drug combinations than our analysis, however they found that 
opioids were the most prevalent drug class involved in potentially inappropriate 
concurrent use combinations (96% of individuals who were prescribed at least one 
instance of potentially inappropriate concurrent combinations of drugs). They 
determined that risk factors for concurrent use of inappropriate drug combinations 
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included having a prescription for opioids, being greater than 18 years old, and using a 
controlled substance for greater than 30 days.15 
Another study which found similar results, compared laboratory drug 
screening test result data to provider supplied prescription information, for both 
prescriptions written by the clinician who order the drug screening, and other drugs 
that the patient was prescribed, which were obtained from the PDMP.  All subjects 
included in this study were prescribed either a benzodiazepine and/or an opioid.  This 
study concluded that concomitant use of benzodiazepines and opioids were more 
common in women (P<0.01), and that this result was driven by the increased number 
of benzodiazepine prescriptions which women received (32.7% vs 23.5%).  They also 
found that the use of benzodiazepines, opioids and the concomitant use of both drugs 
increased with age.16  
 We also found that older age increases risk for concomitant opioid and 
benzodiazepine use, which is supported by findings that older adults may suffer from 
more chronic pain,17 and are prescribed benzodiazepines for a range of maladies 
including, insomnia and anxiety.18  We theorized that an individual who was 
prescribed concomitant opioid and benzodiazepine drugs was more likely to have a 
greater number of prescribers; this theory was confirmed by our findings.  Patients 
who saw greater than two prescribers were more likely to receive concomitant therapy.  
These patients may have more complicated medical conditions requiring them to see 
more physicians, but the care may not be well coordinated.  Another potential 
explanation of this finding is timing of the implementation of the PDMP with relation 
to our study year.  One goal of implementation is to encourage prescribers to consult 
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the database prior to prescribing medications, however through the end of 2015 (the 
year of the study), only about 40% of prescribers had registered with the PDMP.  
Further analysis with subsequent years of data may find different results; as of 
September, 2016, 100% of Rhode Island prescribers were registered with the PDMP.19 
Lastly, patients who were prescribed stimulant medications were less likely to be 
prescribed opioids and benzodiazepines as concomitant therapy.  We included 
stimulant use as a covariate due to its potential for abuse.  While stimulant use (and 
subsequent abuse) has been historically seen in younger populations,20 stimulant 
dependence and abuse has been reported in older adult populations as well.21  
Much of the published literature surrounding concomitant use of 
benzodiazepines and opioids discusses changes in prescribing patterns over time,22 the 
detrimental effects of concomitant use of these drugs, including death,5,11,23,24 and 
socio-economic factors that predict concomitancy.13,22,25  While these topics are 
important and relevant to the current climate of pharmaceutical prescribing, these are 
not factors that we can consider with the data utilized in our study.  In addition to its 
primary purpose as a real-time tool to aid prescribers and pharmacists in making the 
best decisions for their patients with timely information about patients’ prescription 
history, PDMP data provide opportunity for state-wide evaluation of patterns of 
controlled substance use, such as our study, that inform public health efforts to 
promote safe and evidence-based use of higher-risk medications.   
 
Limitations: 
While the PDMP dataset lacks certain basic demographic information, such as 
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race/ethnicity, other variables which are captured in the database have been reported 
as predictors in published literature and were consistent with our findings, including 
age, and a single provider who writes concomitant prescriptions.22 
This study has several limitations in its current state, some of which can be 
addressed in future analysis, and others that are limitations of the dataset.  Limitations 
which will be addressed in subsequent analysis are identifying and determining the 
significance of other prescribed scheduled medications, identifying prescribers who 
write the most prescriptions for opioids, benzodiazepines, and the concomitant use of 
these medications.  It is possible that some providers are unaware of their patient’s 
concomitant therapy while others may be prescribing it knowingly.  Further sub-group 
analyses will provide more insight into these factors. 
Limitations that we cannot address through a more thorough analysis include a 
lack of diagnosis information, use of non-scheduled drugs, race, socio-economic status 
attributes including income, education, transportation, housing status, marital status – 
all which may be of interest but are beyond the scope of this research and database.  
We excluded patients who we determined to be receiving end-of-life care or cancer 
treatment, without diagnosis code this determination was based on the type of 
prescription that a patient filled.  It is possible that we over or under-estimated the 
number of patients with these conditions. 
We conclude that there are predictive factors that can be observed in pharmacy 
level data to determine if a patient is at a higher risk for being prescribed concomitant 
benzodiazepine and opioid therapy.  These factors are age greater than or equal to 45 
years, using health insurance to pay for controlled substance prescriptions (rather than 
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cash) and receiving controlled substance prescriptions from greater than two 
prescribers.
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APPENDICES 
Table 1. Characteristics of 139,410 patients who received opioid and/or 
benzodiazepine prescriptions from RI pharmacies in 2015 
 Characteristic 
Concomitant Use  Opioid Only 
Benzodiazepine 
Only 
Dual use no 
overlap Total   
p value (% of Total) (% of Total) (% of Total) (% of Total) 
n = 21652 (15.5)  n = 34825 (25) n = 81062 (58.1) n = 1871 (1.3) N = 139410 
Age 
Age Mean, (SD) 59.2 (15.7) 59.4 (17.2) 51.4 (19.3) 57.6 (17.1) 54.8 (18.7) <0.00011 
Age Group, N (%) 
<19 47 (<1) 491 (1.4) 3705 (4.6) 9 (<1) 4253 (3) 
<0.0001 
19 -24 117 (<1) 350 (1) 3910 (4.8) 32 (<1) 4413 (3.2) 
25 – 44 3474 (16) 5313 (15.3) 20287 (25) 389 (20.1) 29539 (21.1) 
45 – 64 10642 (49.2) 15773 (45.3) 32462 (40.1) 801 (42.8) 59909 (42.8) 
> 64 7372 (34.1) 12898  (37) 20698 (25.5) 640 (34.21) 41780 (29.9) 
Gender, N (%) 
Male 7363 (34) 16304 (46.8) 27062 (33.4) 660 (35.3) 51598 (36.9) 
<0.0001 
Female 14288 (66) 18515 (53.2) 53977 (66.6) 1211 (64.7) 88266 (63.1) 
Payment type, N (%) 
Cash 1881 (8.7) 3570 (10.2) 11302 (13.9) 204 (10.9) 16916 (12.1) 
<0.0001 
Public 5914 (27.3) 10255 (29.2) 13298 (16.4) 457 (24.4) 30018 (21.5) 
Commercial 13152 (60.7) 20456 (58.2) 56007 (69.1) 1163 (62.2) 90877 (65) 
Other 705 (3.3) 888 (2.5) 454 (<1) 47 (2.5) 862 (2.5) 
Total Number of prescribers (all opioids and/benzodiazepines) N (%) 
<= 3 13456 (62.2) 33867 (96.3) 80283 (99) 1348 (72) 125118 (89.4) 
<0.0001 
> 3 8196 (37.8) 1301 (3.7) 779 (1) 1523 (28) 14776 (10.6) 
Total Number of pharmacies used to fill opioid and/or benzodiazepine prescriptions, N (%) 
<= 3 17572 (81.2) 31882 (91.6) 80184 (98.9) 1673 (89.4) 131727 (94.2) 
<0.0001 
> 3 4080 (18.8) 2943 (8.4) 878 (1.1) 198 (10.6) 8168 (5.8) 
Total Prescriptions for controlled substances, Mean (SD) 
  24.2 (15.7) 10.5 (9.9) 6.2 (7.0) 9.8 (7.7) 6.7(7.3) <0.00011 
Stimulant Use, Filled at least one prescription in 2015, N (%) 
  1498 (6.9) 950 (2.7) 5205 (6.4) 125 (6.7) 7794 (5.6) <0.0001 
 
1Performed Student t-test using Concomitant use compared to all other categories combined  
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Table 2. Adjusted odds of receiving concomitant opioid and benzodiazepine 
prescriptions, and compared with using either medication separately (N = 139,410). 
Characteristic  Odds Ratio 95% CI1 p Value 
Age (Ref = 25-44) 
<= 18 0.231 0.17 0.32 <.0001 
19 – 24 0.343 0.28 0.43 <.0001 
45 – 64 1.326 1.259 1.398 <.0001 
>= 65 1.85 1.75 1.96 <.0001 
Payment Type (Ref = Cash) 
Commercial Insurance 1.003 0.943 1.067 0.9268 
Public Insurance 1.108 1.035 1.185 0.003 
Other 3.684 3.249 4.177 <.0001 
Unique Prescribers (Ref = > 3 Prescribers) 
<= 3 Prescribers 0.257 0.246 0.268 <.0001 
Total Number of 
Prescriptions 
1.119 1.117 1.121 <.0001 
Stimulant Use  
(Ref = None) 
3.226 2.967 3.509 <.0001 
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Table 3.  Opioid and Benzodiazepine Use in the Concomitant Use Group: 
Medication Type, 1 Number of Prescriptions, Total Days’ Supply and Patients 
receiving Medication from Different Prescribers 
Medication N (%) 
  Oxycodone 11,694 (54) 
  Hydrocodone 10617 (49) 
  Morphine 3143 (14.5) 
  Codeine 1905 (8.8) 
  Fentanyl 1159 (5.4) 
  Hydromorphone 955 (4.4) 
  Methadone 426 (2) 
  Oxymorphone 116 (<1) 
  Tapentadol 93 (<1) 
  Pentazoncine 23 (<1) 
  Buterophanol 23 (<1) 
  Meperidine 20 (<1) 
  Levorphanol 1 (<1) 
Benzodiazepine Type, N (%) 
  Alprazolam 6518 (28.2) 
  Lorazepam 5618 (24.3) 
  Clonazepam 5602 (24.2) 
  Diazepam 4663 (20.2) 
  Temazepam 515 (2.2) 
  Clorazepate 91 (<1) 
  Chlordiazepoxide 53 (<1) 
  Triazolam 46 1) 
  Oxazepam 18 (<1) 
  Flurazepam 12 (<1) 
  Estrazolam 3 (<1) 
Average number of opioid prescriptions by duration of action, Mean (SD) 
  Short Acting 9.3 (6.7) 
  Long Acting 1.7 (4.5) 
Average Number of Prescriptions, Mean (SD) 
  Opioids 10 (7) 
  Benzodiazepines 7 (5) 
Average Days of Supply, Mean (SD) 
  Opioids 174.8 (117.2) 
  Benzodiazepines 169.7 (125) 
  Overlapping days 10.2(10.2) 
Different Prescribers, N (%) 
  At least one instance of concomitant opioid and benzodiazepine 
prescriptions were prescribed by different prescribers 
12861 (59.4) 
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Table 4.  Receipt of an Opioid Prescription by a top 25%, 10% and 5% Opioid 
Prescriber by Total Prescription Volume, in the Concomitant Use Group. 
Patient filled at least one prescription written by a prescriber who was in the top  
25% of opioid prescribers  21595 (99.7) 
10% of opioid prescribers 7359 (34) 
5% of opioid prescribers 4073 (18.8) 
 
 
Table 5. Opioid and Benzodiazepine Use in the Concomitant Use Group, Stratified 
by Gender: Medication Type,1 Number of Prescriptions, Total Days’ Supply. 
  
Male Female 
p Value 
n = 7363 n = 14288 
Age 
Age Mean, Mean (SD) 57.7 (14.3) 60.04 (16.3) <0.0001 
Age Group, N (%) 
<19 19 (<1) 28 (<1) 
<0.0001 
19 -24 45 (<1) 72 (<1) 
25 – 44 1190 (16.2) 2283 (16) 
45 – 64 3968 (53.9) 6674 (46.7) 
> 64 2141 (29.1) 5231 (36.6) 
Payer, N (%) 
Cash 626 (8.5) 1255 (8.8) 
<0.0001 
Public 1792 (24.3) 4122 (28.9) 
Commercial 4691 (63.7) 8460 (59.2) 
Other 254 (3.5 451 (3.2) 
Number of Prescribers, N (%) 
<= 3 4691 (63.7) 8764 (61.3) 
0.0007 
> 3 2672 (36.3) 5524 (38.7) 
Number of Unique Pharmacies, N (%) 
<= 3 5924 (80.5) 11648 (81.5) 
0.0572 
> 3 1439 (19.5) 2640 (18.5) 
Total Prescriptions, Mean (SD) 
Any prescriptions reported in the 
PDMP 
24.2 (15.7) 24.0 (15.6) 0.0015 
Stimulant Use, N (%) 
Filled at least one prescription in 
2015 
424 (5.8) 1074 (7.5) <0.0001 
Total Prescriptions, Mean (SD) 
  23.6 (15.4) 24.5 (15.8) <0.0001 
1 One case was removed for gender variable not recorded 
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Table 6. Opioid and Benzodiazepine Use in the Concomitant Use Group, Stratified 
by Gender: Chemical Type, Number of Prescriptions, Total Days Supply1 and 
Inconsistent Prescribers. 
Chemical Type, N (%) 
 Male Female p Value 
Oxycodone 4363 (59.3) 7330 (51.3) <0.0001 
Morphine 1175 (16) 1968 (13.8) <0.0001 
Codeine 476 (6.5) 1429 (10) <0.0001 
Methadone 179 (2.4) 247 (1.7) 0.0004 
Average number of prescriptions by duration of Action, Mean (SD) 
Long Acting 2.0 (4.8) 1.6 (4.3) <0.0001 
Average Number of Prescriptions, Mean (SD) 
Opioids 10 (7) 7.4 (4) <0.0001 
Benzodiazepines 6.6 (5) 7.1 (5.1) <0.0001 
Average Days of Supply, Mean (SD) 
For Opioids 178.7 (119.5) 172.7 (115.9) 0.0025 
For Benzodiazepines 161.3 (126.9) 174 (123.8) <0.0001 
Different Prescribers, N (%) 
At least one instance of 
concomitant opioid and 
benzodiazepine 
prescriptions were 
prescribed by different 
prescribers 
4188 (56.9) 8673 (60.7) <0.0001 
1Significant independent variables included 
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Figure 1. Flow chart for selection criteria of study participants 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Final Outcome Groups1
Received 
benzodiazepines and/or 
>= 30 days of opioids
Complete Prescription 
Claim information, did 
not receive prescription 
for opioid to treat cancer 
pain
Receipt of 
Benzodiazepine and/or  
Opioid Prescriptions 
2015 Only
Initial PDMP Database
N = 
409,740
n = 
364,128
n = 
326,785
n = 
297,594
n = 
139,410
n = 21,652 n = 34,825 n = 81,062 n = 1,871
1From left to right: Concomitant use of opioids and benzodiazepines, opioid use only, benzodiazepine 
use only, non-concomitant use of opioids and benzodiazepines. 
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Appendix 1. Sensitivity Analysis of Number of Days of Overlapping 
Benzodiazepine and Opioid Prescriptions Dispensed in RI pharmacies in 2015, in 
the Concomitant Use Group  
 
Concomitant 
Use1 
No Overlap2 
At least 2 days 
of overlap 
At least 3 days of 
overlap p Value 
n = 21652 n = 22136 n = 21276 n = 20890 
Age* 
Age Mean 59.2 (15.7) 59.2 (15.7) 59.4 (17.2) 51.4 (19.3) 0.96 
Age Group 
<19 47 (<1) 48 (<1) 46 (<1) 44 (<1) 
>.99 
19 -24 117 (<1) 121 (<1) 113 (<1) 108 (<1) 
25 – 44 3474 (16) 3550 (16) 3397 (16) 3314 (15.9) 
45 – 64 10642 (49.2) 10873 (49.1) 10457 (49.2) 10286 (49.2) 
> 64 7372 (34.1) 7544 (34.1) 7263 (34.1) 7138 (34.2) 
Gender 
Male 7363 (34) 7572 (34.2) 7213 (33.9) 7046 (33.7) 
0.98 
Female 14288 (66) 14563 (65.8) 14062 (66.1) 13843 (66.3) 
Payer 
Cash 1881 (8.7) 1924 (8.7) 1851 (8.7) 1819 (8.7) 
>.99 
Public 5914 (27.3) 6058 (27.4) 5819 (27.4) 5746 (27.5) 
Commercial 13152 (60.7) 13435 (60.7) 12915 (60.7) 12650 (60.6) 
Other 705 (3.3) 719 (3.3) 691 (3.3) 675 (3.2) 
Number of prescribers 
<= 3 13456 (62.2) 13758 (62.1) 13248 (62.3) 13025 (62.4) 
0.97 
> 3 8196 (37.8) 8378 (37.9) 8028 (37.7) 7865 (37.7) 
Pharmacy Utilization 
<= 3 17572 (81.2) 17988 (81.3) 17252 (81.1) 16929 (81) 
0.94 
> 3 4080 (18.8) 4148 (18.7) 4024 (18.9) 3961 (19) 
Total Prescriptions* 
 24.2 (15.7) 24.0 (15.6) 24.4 (15.7) 24.6 (15.7) >.99 
Stimulant Use 
Filled at 
least one 
prescription in 
2015 
1498 (6.9) 1514 (6.8) 1482 (7) 1460 (7) 0.93 
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